Dr. Lam’s Vaccine
What is the Peptide Vaccine Trial for Advanced ALK+ Lung Cancer?
A new clinical trial at Johns Hopkins is testing a cutting-edge peptide vaccine designed for people with advanced ALK+ non-small cell lung cancer (NSCLC). The goal? To prevent or delay resistance to ALK-targeted therapies, potentially keeping the cancer under control for longer.
Who's Behind It?
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, led by Dr. Vincent Lam.
What’s ALK+ NSCLC?
ALK+ means the lung cancer has a specific genetic fusion (ALK) that can be targeted with precision drugs. But over time, the cancer can outsmart these treatments. This trial is about slowing or stopping that resistance before it happens.
How Does the Peptide Vaccine Work?
Think of it as a training program for your immune system. The vaccine teaches immune cells to recognize and attack resistant ALK cancer cells—before they emerge. It’s like prepping a superhero squad for future battles.
Why It Matters
Vaccines are the new frontier Targeted cancer vaccines are one of the most promising frontiers in ALK+ lung cancer research. While our primary focus is supporting Dr. Lam’s vaccine at Johns Hopkins, we’re closely following other emerging approaches and committed to championing the paths with the greatest potential impact. Vaccines hold incredible promise to transform how we fight this disease—and save countless lives.